MeiraGTx is a clinical-stage genetic medicine company focused on developing potentially curative treatments for serious diseases. The company is pioneering technologies that allow precise control of gene expression using proprietary oral small molecules, with applications in treating inherited diseases and other conditions.

MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

MeiraGTx Holdings plc

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Sep 17, 2024 6:00 AM	cc7a8ca1
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Sep 17, 2024 6:00 AM	737b3926
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 17, 2024 6:00 AM	3440355f
news basic	general	Sep 17, 2024 6:00 AM	91765d8b
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:MEIRAGTX

MeiraGTx

Last Close

6.73

08/11 21:00

Market Cap

266.23M

Beta: -

Volume Today

544.00K

Avg: -